Eculizumab Is Associated with Significantly Lower Adenovirus Clearance in Children after Hematopoietic Cell Transplantation

Key Points

• Lower adenovirus clearance was observed in children receiving eculizumab, impacting viral recovery rates.
• Clearance rates were significantly reduced, indicating a strong connection between eculizumab and delayed recovery from adenovirus.
• Observational analysis of pediatric transplant patients highlighted the immunosuppressive effects of eculizumab.
• Implications of reduced adenovirus clearance need further exploration in larger populations to confirm findings.